Literature DB >> 28877312

Effect of Topical Fluorouracil Cream on Photodamage: Secondary Analysis of a Randomized Clinical Trial.

Kaveri Korgavkar1, Kachiu C Lee1, Martin A Weinstock1,2.   

Abstract

Importance: Photoaging, which is premature skin aging caused by long-term UV exposure, is of aesthetic concern to many patients. Objective: To investigate the effect of topical fluorouracil, 5%, cream on photoaging using validated photonumeric scales. Design, Setting, and Participants: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial was a randomized clinical trial of 932 US veterans with a recent history of 2 or more keratinocyte carcinomas performed from September 30, 2011, through June 30, 2014, to assess the chemopreventive effects of a standard course of topical fluorouracil. Photographs were taken at baseline and at numerous time points for up to 4 years. In our secondary analysis, 2 independent dermatologists graded these photographs using 4 validated photonumeric scales. A total of 3042 photographs from 281 participants randomized to apply topical fluorouracil or placebo were evaluated at baseline, 6 months, 12 months, and 18 months using 4 photonumeric scales (Griffiths scale, Allergan forehead lines scale, melomental folds scale, and crow's feet scale). Data analysis was performed from November 1, 2016, to January 1, 2017. Interventions: Participants were randomized to apply topical fluorouracil, 5%, cream or a vehicle control cream to the face and ears twice daily for 2 to 4 weeks for a total of 28 to 56 doses. Main Outcomes and Measures: Effect of a standard course of fluorouracil on the extent of photodamage as measured using 4 photonumeric scales.
Results: The study population was predominantly male (274 [97.5%]) and white (281 [100%]), with a mean (SD) age of 71.5 (0.57) years. No statistically significant changes were found in photodamage between baseline and 6 months (Griffiths scale: χ2 = 0.01, P = .93; Allergan forehead lines scale: χ2 = 0.18, P = .67; melomental fold scale: χ2 = 0.03, P = .87; crow's feet scale: χ2 = 2.41, P = .12), 12 months (Griffiths scale: χ2 = 1.39, P = .24; Allergan forehead lines scale: χ2 = 0.64, P = .43; melomental fold scale: χ2 = 0.12, P = .73; crow's feet scale: χ2 = 1.07, P = .30), and 18 months (Griffiths scale: χ2 = 3.11, P = .08; Allergan forehead lines scale: χ2 = 0.89, P = .34; melomental fold scale: χ2 = 1.64, P = .20; crow's feet scale: χ2 = 0.46, P = .50). Conclusions and Relevance: This study did not demonstrate improvement in photoaging with a standard course of topical fluorouracil, 5%, cream, a finding that may be attributable to a true lack of effect in photodamage or limitations of the photonumeric scales in capturing the effect. The development of photonumeric scales that include manifestations of photoaging other than rhytids, such as lentigines, hyperpigmentation, and telangiectasias, should be considered. Trial Registration: clinicaltrials.gov Identifier: NCT00847912.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28877312      PMCID: PMC5710428          DOI: 10.1001/jamadermatol.2017.2578

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  26 in total

1.  Skin changes in patients treated with 5-fluorouracil.

Authors:  G FALKSON; E J SCHULZ
Journal:  Br J Dermatol       Date:  1962-06       Impact factor: 9.302

Review 2.  Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.

Authors:  Roger I Ceilley
Journal:  J Dermatolog Treat       Date:  2010-10-31       Impact factor: 3.359

Review 3.  Photoageing: mechanism, prevention and therapy.

Authors:  M Yaar; B A Gilchrest
Journal:  Br J Dermatol       Date:  2007-08-17       Impact factor: 9.302

4.  A validated grading scale for crow's feet.

Authors:  Alastair Carruthers; Jean Carruthers; Bhushan Hardas; Mandeep Kaur; Roman Goertelmeyer; Derek Jones; Berthold Rzany; Joel Cohen; Martina Kerscher; Timothy Corcoran Flynn; Corey Maas; Gerhard Sattler; Alexander Gebauer; Rainer Pooth; Kathleen McClure; Ulli Simone-Korbel; Larry Buchner
Journal:  Dermatol Surg       Date:  2008-11       Impact factor: 3.398

Review 5.  Topical Retinoids: Therapeutic Mechanisms in the Treatment of Photodamaged Skin.

Authors:  Ryan R Riahi; Amelia E Bush; Philip R Cohen
Journal:  Am J Clin Dermatol       Date:  2016-06       Impact factor: 7.403

6.  The polyhydroxy acid gluconolactone protects against ultraviolet radiation in an in vitro model of cutaneous photoaging.

Authors:  Eric F Bernstein; Douglas B Brown; Mark D Schwartz; Kays Kaidbey; Sergey M Ksenzenko
Journal:  Dermatol Surg       Date:  2004-02       Impact factor: 3.398

7.  Development and Validation of a Photonumeric Scale for Assessment of Chin Retrusion.

Authors:  Jonathan M Sykes; Alastair Carruthers; Bhushan Hardas; Diane K Murphy; Derek Jones; Jean Carruthers; Lisa Donofrio; Lela Creutz; Ann Marx; Sara Dill
Journal:  Dermatol Surg       Date:  2016-10       Impact factor: 3.398

8.  Development and Validation of a Photonumeric Scale for Evaluation of Volume Deficit of the Hand.

Authors:  Derek Jones; Lisa Donofrio; Bhushan Hardas; Diane K Murphy; Jean Carruthers; Alastair Carruthers; Jonathan M Sykes; Lela Creutz; Ann Marx; Sara Dill
Journal:  Dermatol Surg       Date:  2016-10       Impact factor: 3.398

9.  Development and Validation of a Photonumeric Scale for Evaluation of Static Horizontal Forehead Lines.

Authors:  Alastair Carruthers; Lisa Donofrio; Bhushan Hardas; Diane K Murphy; Jean Carruthers; Jonathan M Sykes; Derek Jones; Lela Creutz; Ann Marx; Sara Dill
Journal:  Dermatol Surg       Date:  2016-10       Impact factor: 3.398

10.  Development and Validation of a Photonumeric Scale for Evaluation of Volume Deficit of the Temple.

Authors:  Jean Carruthers; Derek Jones; Bhushan Hardas; Diane K Murphy; Lisa Donofrio; Jonathan M Sykes; Alastair Carruthers; Lela Creutz; Ann Marx; Sara Dill
Journal:  Dermatol Surg       Date:  2016-10       Impact factor: 3.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.